HSL119 results in gene expression changes equivalent to HUNK shRNA

The goal of this study was to determine the gene similarities and overlap between human HER2+ breast cancer cells treated with a HUNK inhibitor (HSL119) and samples engineered with HUNK shRNA (KD1 and KD2). A main objective was to determine if genes related to the AKT pathway were changed in HUNK treated or HUNK knockdown groups compared to control. Total of 15 samples: HSL (n=3), CTL (n=4), HUNK KD1 (n=4), HUNK KD2 (n=4). CTL is the control/reference sample.